Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01138306|
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from young patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Genetic: mutation analysis Other: flow cytometry Other: laboratory biomarker analysis|
- Determine the extent and prognostic implications of variable s-SHIP expression and SHIP gene mutations in pediatric patients with acute myeloid leukemia.
- Determine the effects of aberrant s-SHIP expression on the PI3K/Akt pathway in these patients via electrochemiluminescence and phosphospecific flow cytometry assays.
OUTLINE: RNA samples are analyzed for variable s-SHIP expression and are screened for SHIP mutations. Cryopreserved cells (with known high- or low-s-SHIP expression) are analyzed for the levels of various components of the PI3K/Akt pathway via electrochemiluminescence and phosphospecific flow cytometry.
|Study Type :||Observational|
|Estimated Enrollment :||149 participants|
|Observational Model:||Case Control|
|Official Title:||Implications of s-SHIP Expression and SHIP Alterations in AML|
|Study Start Date :||February 2013|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
- Event-free survival
- Overall survival
- Relapse rate
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138306
|Principal Investigator:||Phoenix Ho, MD||Fred Hutchinson Cancer Research Center|